Castle Creek Biosciences
PrivateLast Round
Debt
Feb 25, 2025
Est. Valuation
$63.3M
Total Funding Raised
$272.9M
Company Overview
Castle Creek Biosciences operates in Healthcare & Life Sciences and is based in Exton, Pennsylvania. Its latest recorded funding round was a Debt round in February 2025.
Castle Creek Biosciences is a biotechnology company that develops personalized cell and gene therapies aimed at addressing the root causes of rare skin and connective tissue diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Castle Creek Biosciences Comparables
Compare Castle Creek Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Abeona Therapeutics Inc. | 81% | |
| Wings Therapeutics | 81% | |
| Krystal Biotech, Inc. | 79% |
For institutional investors. Book with your work email.
Castle Creek Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Feb 25, 2025 | ||||
| VC Round | May 25, 2022 | ||||
| Convertible Debt | Jun 28, 2021 | ||||
| Series C | Mar 25, 2020 | ||||
| Debt | Mar 25, 2020 | ||||
M&A | Dec 16, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Castle Creek Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ligand Pharmaceuticals | Debt |
| EB Research Partnership | Private Placement |
| Fidelity Management & Research Company | VC Round, Series B, Series C, Convertible Debt |
| Paragon Biosciences | Debt, VC Round, Series B, Series C |
| Horizon Technology Finance Corporation | Debt |
| Valor Equity Partners | Debt, VC Round, Series B, Series C |
| Third Security | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 24, 2026
Lead candidate for dystrophic epidermolysis bullosa (DEB) enters pivotal trial.
- Apr 1, 2025
Lead candidate for DEB moves to pivotal Phase 3 trial, nearing BLA filing.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 30, 2026
Castle Creek Biosciences, Inc. is using its proprietary fibroblast technology to develop a topical formulation of D-Fi and pursue additional therapeutic targets for serious skin diseases, including malignancies and inflammatory conditions.
For institutional investors. Book with your work email.
Castle Creek Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Castle Creek Biosciences's valuation, stock price, and market status.
Is Castle Creek Biosciences a public or private company?
Castle Creek Biosciences is a private company.
What is the current stock price of Castle Creek Biosciences?
Castle Creek Biosciences is a private company, so its shares have no public market price. Caplight tracks Castle Creek Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Castle Creek Biosciences worth (valuation)?
Castle Creek Biosciences's valuation is estimated at $63.3M based on funding round data.
Can I buy Castle Creek Biosciences stock?
Castle Creek Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Castle Creek Biosciences's last funding round?
Castle Creek Biosciences's most recent funding round was Debt on February 25, 2025.
Who are the main investors in Castle Creek Biosciences?
Key investors in Castle Creek Biosciences include Ligand Pharmaceuticals, Fidelity Management & Research Company, Paragon Biosciences.
Will Castle Creek Biosciences IPO soon?
No public IPO plans have been announced for Castle Creek Biosciences.
How can I track Castle Creek Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Castle Creek Biosciences's shares on secondary markets.